Benazepril+Losartan

PreclinicalSmall molecule

NNanfang Hospital, Southern Medical University

Benazepril+Losartan is one of 33 small molecule programs targeting Renal insufficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal InsufficiencyActive, not recruiting

Renal InsufficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Renal Insufficiency

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Aliqopa

Jaypirca

Gilenya

Retevmo

Cubicin

BBaxter Healthcare Corporation

Approved

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 8

Genotropin

EMD Serono

Approved

1 9

Zocor

OOrganon and Co

Approved

1 10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal insufficiency1 trial

Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency

Terminated·NNanfang Hospital, Southern Medical University·N/A·NCT00630708·309 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Benazepril+Losartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benazepril+Losartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benazepril+Losartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNanfang Hospital, Southern Medical University

Benazepril+Losartan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal insufficiency1 trial

References

Drug Info

Quick Facts

Related News